



## **Modigene to Present at the BIO-Europe Spring<sup>®</sup> 2009 Conference**

**Nes-Ziona, Israel March 10, 2009** -- Modigene Inc. (OTCBB: MODG), a biopharmaceutical company developing a long-acting human growth hormone and other proprietary longer-acting versions of already approved therapeutic proteins, today announced that CEO Avri Havron will present at the upcoming BIO-Europe Spring<sup>®</sup> 2009 Conference at 10:00 AM (local time) on March 17, 2009. The conference is held at the Milano Convention Center in Milan, Italy from March 16-18, 2009.

For more information about the BIO-Europe Spring<sup>®</sup> 2009 Conference, visit <http://www.ebdgroup.com/bes/>

### **ABOUT MODIGENE**

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit [www.modigeneinc.com](http://www.modigeneinc.com).

MODIGENE CONTACT:  
Shai Novik, President  
Modigene Inc.  
Tel: +1 866 644-7811  
Email: [shai@modigeneinc.com](mailto:shai@modigeneinc.com)

MEDIA CONTACT:  
Barbara Lindheim  
GendeLLindheim BioCom Partners  
+1 212 918-4650